ZUR SACHE
European Medicines Agency: From Business as it used to be to New Horizons

PRO & CONTRA
Paediatric Investigation Plans (PIPs): Chance oder Nachteil – eine Entgegnung

CONSILIUM
AMNOG meets EMA—Methodological Areas of Debate from an Industry Point of View